Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 473
Filtrar
1.
Nefrologia (Engl Ed) ; 2024 Apr 17.
Artículo en Inglés | MEDLINE | ID: mdl-38637262

RESUMEN

BACKGROUND: Studies analyzing non-antibiotic alternatives in kidney transplant UTI's are lacking. d-Mannose, a simple sugar, inhibits bacterial attachment to the urothelium, as does Proanthocyanidins; both could act as a synergic strategy preventing UTI; nonetheless their efficacy and safety have not been evaluated in kidney transplant population yet. METHODS: This is a pilot prospective, double-blind randomized trial. Sixty de novo kidney transplant recipients were randomized (1:1) to receive a prophylactic strategy based on a 24-h prolonged release formulation of d-Mannose plus Proanthocyanidins vs. Proanthocyanidins (PAC) alone. The supplements were taken for the first 3 months after kidney transplant and then followed up for 3 months as well. The main objective of the study was to search if the addition of Mannose to PAC alone reduced the incidence of UTI and/or asymptomatic bacteriuria in the first 6 months post-transplantation. RESULTS: 27% of patients experienced one UTI episode (cystitis or pyelonephritis) while asymptomatic bacteriuria was very common (57%). Incidences according UTI type or AB were: 7% vs. 4% for cystitis episode (p 0.3), 4% vs. 5% for pyelonephritis (p 0.5) and 17% vs. 14% for asymptomatic bacteriuria (p 0.4) for patients in the Mannose+PAC group vs. PAC group respectively. The most frequent bacteria isolated in both groups was Escherichia coli (28% of all episodes), UTI or AB due to E. coli was not different according to study group (30% vs. 23% for Mannose+PAC vs. PAC alone p 0.37). CONCLUSIONS: Non-antibiotic therapy is an unmet need to prevent UTI after kidney transplantation; however, the use of d-Mannose plus PAC does not seem capable to prevent it.

2.
Nefrologia (Engl Ed) ; 2024 Apr 12.
Artículo en Inglés | MEDLINE | ID: mdl-38614890

RESUMEN

BACKGROUND AND JUSTIFICATION: The strategy of the concentration-dose (C/D) approach and the different profiles of tacrolimus (Tac) according to the cytochrome P450 polymorphisms (CYPs) focus on the metabolism of Tac and are proposed as tools for the follow-up of transplant patients. The objective of this study is to analyse both strategies to confirm whether the stratification of patients according to the pharmacokinetic behaviour of C/D corresponds to the classification according to their CYP3A4/5 cluster metabolizer profile. MATERIALS AND METHODS: 425 kidney transplant patients who received Tac as immunosuppressive treatment have been included. The concentration/dose ratio (C/D) was used to divide patients in terciles and classify them according to their Tac metabolism rate (fast, intermediate, and slow). Based on CYP3A4 and A5 polymorphisms, patients were classified into 3 metabolizer groups: fast (CYP3A5*1 carriers and CYP34A*1/*1), intermediate (CYP3A5*3/3 and CYP3A4*1/*1) and slow (CYP3A5*3/*3 and CYP3A4*22 carriers). RESULTS: When comparing patients included in each metabolizer group according to C/D ratio, 47% (65/139) of the fast metabolizers, 85% (125/146) of the intermediate and only 12% (17/140) of the slow also fitted in the homonym genotype group. Statistically lower Tac concentrations were observed in the fast metabolizers group and higher Tac concentrations in the slow metabolizers when compared with the intermediate group both in C/D ratio and polymorphisms criteria. High metabolizers required approximately 60% more Tac doses than intermediates throughout follow-up, while poor metabolizers required approximately 20% fewer doses than intermediates. Fast metabolizers classified by both criteria presented a higher percentage of times with sub-therapeutic blood Tac concentration values. CONCLUSION: Determination of the metabolizer phenotype according to CYP polymorphisms or the C/D ratio allows patients to be distinguished according to their exposure to Tac. Probably the combination of both classification criteria would be a good tool for managing Tac dosage for transplant patients.

3.
Nefrología (Madrid) ; 44(2): 204-216, Mar-Abr. 2024. tab, graf
Artículo en Español | IBECS | ID: ibc-231570

RESUMEN

Antecedentes y justificación: La estrategia de la aproximación concentración-dosis (C/D) y los distintos perfiles del tacrolimus (Tac), según los polimorfismos del citocromo P450 (CYPs) se centran en el metabolismo de Tac y se plantean como herramientas para el seguimiento de los pacientes trasplantados. El objetivo de este estudio es comparar la exposición al Tac analizado según ambas estrategias. Materiales y métodos: Se han incluido 425 pacientes trasplantados renales. El cálculo del cociente concentración Tac/dosis (C/D) permitió dividir la población en terciles y clasificar los pacientes según su tasa de metabolismo del Tac en tres grupos (rápida, intermedia y lenta). Con base en los polimorfismos del CYP3A4 y A5, los pacientes se agruparon en metabolizadores rápidos (portadores del CYP3A5*1 y CYP34A *1/*1), intermedios (CYP3A5*3/3 y CYP3A4*1/*1) y lentos (CYP3A5 *3/*3 y portadores del CYP3A4*22). Resultados: Al comparar los pacientes de cada grupo metabolizador según los dos criterios, coincidieron 47% (65/139) de los metabolizadores rápidos, 85% (125/146) de los intermedios y solo 12% (17/140) de los lentos. Se observaron concentraciones de Tac estadísticamente menores en los metabolizadores rápidos y concentraciones mayores en los lentos, comparándolos con el grupo intermedio según el cociente C/D o según polimorfismos. Los metabolizadores rápidos requirieron alrededor de 60% más de dosis de Tac que los intermedios a lo largo del seguimiento, mientras que los lentos aproximadamente 20% menos de dosis que los intermedios. Los metabolizadores rápidos clasificados por ambos criterios presentan un porcentaje mayor de veces con valores de concentración de Tac en sangre infraterapéuticos... (AU)


Background and justification: The strategy of the concentration–dose (C/D) approach and the different profiles of tacrolimus (Tac) according to the cytochrome P450 polymorphisms (CYPs) focus on the metabolism of Tac and are proposed as tools for the follow-up of transplant patients. The objective of this study is to analyse both strategies to confirm whether the stratification of patients according to the pharmacokinetic behaviour of C/D corresponds to the classification according to their CYP3A4/5 cluster metabolizer profile. Materials and methods: Four hundred and twenty-five kidney transplant patients who received Tac as immunosuppressive treatment have been included. The concentration/dose ratio (C/D) was used to divided patients in terciles and classify them according to their Tac metabolism rate (fast, intermediate, and slow). Based on CYP3A4 and A5 polymorphisms, patients were classified into three metabolizer groups: fast (CYP3A5*1 and CYP34A*1/*1 carriers), intermediate (CYP3A5*3/3 and CYP3A4*1/*1) and slow (CYP3A5*3/*3 and CYP3A4*22 carriers). Results: When comparing patients included in each metabolizer group according to C/D ratio, 47% (65/139) of the fast metabolizers, 85% (125/146) of the intermediate and only 12% (17/140) of the slow also fitted in the homonym genotype group. Statistically lower Tac concentrations were observed in the fast metabolizers group and higher Tac concentrations in the slow metabolizers when compared with the intermediate group both in C/D ratio and polymorphisms criteria. High metabolizers required approximately 60% more Tac doses than intermediates throughout follow-up, while poor metabolizers required approximately 20% fewer doses than intermediates. Fast metabolizers classified by both criteria presented a higher percentage of times with sub-therapeutic blood Tac concentration values... (AU)


Asunto(s)
Humanos , Tacrolimus , Trasplante de Riñón , Farmacocinética , Farmacogenética , Metabolismo , Dosificación
4.
Cir Cir ; 92(1): 96-103, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38537238

RESUMEN

OBJECTIVE: To know, analyze and compare kidney transplant programs; considering the survival of recipients at 1 and 5 years, from hospitals in Mexico. METHOD: A systematic review was carried out whose search focused on the survival of kidney transplant recipients. All publications found in PubMed and Google from 1963 to 2021 were included. The expectation-maximization algorithm was applied, proposing a mixture of normals, and hierarchical grouping to establish if there is any type of pattern and determine if there is a difference between the percentages. of survival at 1 and 5 years between the groups formed. RESULTS: Eight hospitals that published the survival of kidney transplant recipients were found. Survival rates ranged, at 1 year, from 94.7% to 100%, and at 5 years, from 85% to 96.2%. The methods used for their comparison indicated that there is a difference between survival at 1 and 5 years. CONCLUSIONS: In Mexico there is little information on the results of kidney transplant programs, and the information found shows great heterogeneity in said programs. Some strategies and actions are proposed to improve survival underreporting.


OBJETIVO: Conocer, analizar y comparar los programas de trasplante renal, considerando la supervivencia de los receptores a 1 y 5 años, en los hospitales en México. MÉTODO: Se realizó una revisión sistemática cuya búsqueda se centró en la supervivencia de los receptores de trasplante renal. Se incluyeron todas las publicaciones encontradas en PubMed y Google de 1963 a 2021. Se aplicó el algoritmo de expectation-maximization, proponiendo una mezcla de normales, y agrupamiento jerárquico para establecer si hay algún tipo de patrón y determinar si hay diferencia entre los porcentajes de supervivencia a 1 y 5 años entre los grupos formados. RESULTADOS: Se encontraron ocho hospitales que publicaron la supervivencia de los receptores de trasplante renal. Los rangos de las tasas de supervivencia fueron, a 1 año, del 94.7% al 100%, y a los 5 años, del 85% al 96.2%. Los métodos empleados para su comparación indican que hay diferencia entre la supervivencia a 1 y 5 años. CONCLUSIONES: En México se tiene poca información sobre los resultados de los programas de trasplante renal, y la información encontrada muestra gran heterogeneidad en dichos programas. Se proponen algunas estrategias y acciones para mejorar el subregistro de supervivencia.


Asunto(s)
Trasplante de Riñón , Humanos , México , Supervivencia de Injerto
5.
Enferm. nefrol ; 27(1): 72-77, ene.-mar. 2024. ilus, tab
Artículo en Español | IBECS | ID: ibc-232077

RESUMEN

Introducción: El trasplante renal precisa de un tratamiento inmunosupresor para evitar el rechazo del injerto, pero éste aumenta el riesgo de contraer una infección. Este riesgo se agrava, aún más, cuando el paciente es portador de una ureterostomía cutánea por la manipulación de las sondas. Descripción Caso Clínico: Varón que ingresa para realización de primer trasplante renal y ureterostomía cutánea. Como antecedentes personales encontramos nefrectomía derecha en 2014 y nefrectomía izquierda y cistectomía radical en 2019, momento en el que comienza en programa de hemodiálisis. Descripción del plan de cuidados: Se realizó valoración inicial y cada 7 días según patrones funcionales de Marjory Gordon. De los diagnósticos identificados a los 15 días se establecieron como prioritarios: Disposición para mejorar los conocimientos, Complicación potencial la infección y Disposición para mejorar el afrontamiento. Evaluación del plan de cuidados: Semanalmente, se revisó el plan de cuidados, cerrando aquellos diagnósticos resueltos. Al alta, tras 33 días ingresado, se alcanzaron los objetivos establecidos, aunque la gran mayoría de ellos se continuaron reevaluando en la Consulta de Enfermería post-trasplante, como fue el diagnóstico de Disposición para mejorar los conocimientos. Conclusiones: Una correcta educación para la salud y la intervención de un equipo interdisciplinar permite un adecua-do aprendizaje de los cuidados fomentando la adherencia terapéutica y una buena prevención y detección precoz de las complicaciones que pueda conllevar la derivación en un paciente trasplantado. Además, ayudar al paciente y a su familia a aceptar esta nueva etapa que conlleva cambios a nivel físico, emocional y social. (AU)


Introduction: Renal transplant requires immunosuppressive treatment to prevent graft rejection, but this increases the risk of infection. This risk is further exacerbated when the patient has a cutaneous ureterostomy due to catheter manipulation. Clinical case description: A male patient was admitted for his first renal transplant and cutaneous ureterostomy. Past medical history includes a right nephrectomy in 2014, a left nephrectomy, and a radical cystectomy in 2019, which led to the initiation of hemodialysis. Nursing care plan description: Initial assessment was conducted, with subsequent evaluations every seven days based on Marjory Gordon’s functional patterns. At the 15-day mark, the following diagnoses were prioritized: Readiness for Enhanced Knowledge, Potential Infection Complication, and Readiness for Enhanced Coping. Evaluation of care plan: The care plan was reviewed weekly, closing out resolved diagnoses. Upon discharge after 33 days of hospitalization, established goals were achieved, with an ongoing revaluation of most of them in the post-transplant Nursing Consultation, particularly the Readiness for Enhanced Knowledge diagnosis. Conclusions: Proper health education and involvement of an interdisciplinary team enable effective learning of care practices, promoting therapeutic adherence and facilitating early prevention and detection of complications that may arise in transplant patients. Additionally, assisting the patient and family in accepting this new phase, which entails physical, emotional, and social changes, is crucial.


Asunto(s)
Humanos , Masculino , Anciano , Trasplante de Riñón/enfermería , Ureterostomía , Atención de Enfermería
6.
Actas urol. esp ; 48(2): 125-133, mar. 2024. graf, tab
Artículo en Español | IBECS | ID: ibc-231444

RESUMEN

Introducción El trasplante renal es el tratamiento de elección para pacientes con enfermedad renal crónica (ERC) estadio 5. Alrededor de 60% de los pacientes con ERC presentan sobrepeso u obesidad en el momento del trasplante de riñón, y la obesidad postrasplante se da en 50% de los pacientes, con un aumento de peso de 10% en el primer año y un alto riesgo de mortalidad cardiovascular. La obesidad se asocia a un mayor riesgo de retraso de la función del injerto (RFI), rechazo agudo, complicaciones quirúrgicas, pérdida del injerto y mortalidad. El objetivo de este estudio es evaluar la evolución clínica de los pacientes obesos y con sobrepeso receptores de un trasplante renal, en términos de las complicaciones a corto y largo plazo asociadas a un mayor índice de masa corporal (IMC). Material y métodos Se realizó un estudio descriptivo, observacional y transversal con 104 pacientes sometidos a trasplante de riñón o páncreas-riñón entre marzo de 2017 y diciembre de 2020, con seguimiento hasta abril de 2021. Para el análisis comparativo, los pacientes se agruparon según el IMC. Resultados La edad media fue de 56,65 años, 60,6% varones y 39,4% mujeres. Los pacientes con sobrepeso experimentaron cirugías más prolongadas, más dehiscencia de la herida quirúrgica, RFI, hernias, proteinuria y un requerimiento mayor de biopsias renales. Por otro lado, los pacientes obesos presentaron más RFI, mayor número de biopsias renales requeridas, proteinuria, desarrollo de diabetes mellitus y fibrilación auricular, y necesitaron estancias hospitalarias más prolongadas. Conclusiones A pesar de la alta prevalencia de comorbilidad en la población con sobrepeso y/u obesidad, no se observó un empeoramiento en la supervivencia del paciente y/o del injerto. Sin embargo, es necesario un seguimiento más prolongado. (AU)


Introduction Kidney transplantation is the treatment of choice for patients with stage 5 chronic kidney disease (CKD). About 60% of CKD patients are overweight or obese at the time of kidney transplantation, and post-transplant obesity occurs in 50% of patients, with a weight gain of 10% in the first year and high risk of cardiovascular mortality. Obesity is associated with an increased risk of delayed graft function (DGF), acute rejection, surgical complications, graft loss and mortality. The aim of this study is to assess the clinical evolution of obese and overweight patients that have received a kidney transplant, based on short- and long-term complications associated with a higher BMI. Material and methods A descriptive, observational, cross-sectional study was conducted with 104 kidney or pancreas-kidney transplant patients between March 2017 and December 2020, with a follow-up until April 2021. For comparative analysis, patients were grouped according to BMI. Results Mean age was of 56.65 years, 60.6% male and 39.4% female. Overweight patients experienced prolonged surgeries, more surgical wound dehiscence, delayed graft function, hernias, proteinuria and more indications for renal biopsies. Additionally, obese patients displayed more DGF, indications for renal biopsies, proteinuria, development of diabetes mellitus, atrial fibrillation and needed prolonged hospital stays. Conclusions Despite a high prevalence of comorbidity in the overweight and/or obese population, we found no reduction in patient and/or graft survival. However, longer follow-up is needed. (AU)


Asunto(s)
Humanos , Obesidad/complicaciones , Sobrepeso , Trasplante de Riñón , Epidemiología Descriptiva , Estudios Transversales
7.
Actas urol. esp ; 48(2): 177-183, mar. 2024. tab, graf
Artículo en Español | IBECS | ID: ibc-231451

RESUMEN

Introducción y objetivos La estenosis de la arteria del injerto renal (EAR) es una complicación vascular del trasplante renal cuya incidencia estimada es del 13%, la cual puede causar hipertensión arterial refractaria, disfunción renal y muerte prematura en los receptores. Métodos Se realizó un estudio retrospectivo que incluyó a todos los pacientes sometidos a trasplante renal entre 2014 y 2020. Los pacientes fueron evaluados mediante ecografía doppler renal sistemática tras el trasplante. Para identificar los factores de riesgo independientes de la estenosis de la arteria renal tras el trasplante, realizamos un análisis multivariante. Resultados Se incluyeron 724 trasplantes renales, el 12% eran de donante vivo y el 88% de donante fallecido. La edad media en los receptores era de 54,8 años y en los donantes era de 53. Se diagnosticó estenosis de la arteria del injerto renal en 70 (10%) receptores, la mayoría durante los primeros 6 meses después de la intervención. El 51% de los pacientes con estenosis de la arteria del injerto renal se manejaron de manera conservadora. El análisis multivariante mostró que la diabetes mellitus, el rechazo del injerto, la resutura arterial y el índice de masa corporal del donante eran factores de riesgo independientes de estenosis de la arteria renal después del trasplante. La supervivencia de los injertos con estenosis de la arteria del injerto renal fue del 98% a los 6 meses y del 95% a los 2 años. Conclusiones El uso sistemático de la ecografía doppler en el período inmediatamente posterior al trasplante permitió diagnosticar un 10% de estenosis de la arteria del injerto renal en nuestra cohorte. A pesar de los factores de riesgo mencionados anteriormente, un seguimiento y tratamiento adecuados podrían reducir el riesgo de pérdida del injerto en pacientes con estenosis de la arteria del injerto renal. (AU)


Introduction and objectives Transplant renal artery stenosis (TRAS) is a vascular complication after kidney transplantation which estimated incidence is 13%. It could cause refractory arterial hypertension, kidney dysfunction and premature death in transplant recipients. Methods We carried out a retrospective study including every patient who underwent renal transplantation between 2014 and 2020. They were evaluated with a systematic post-transplant renal Doppler ultrasound. To identify independent risk factors for transplant renal artery stenosis we performed a multivariate analysis. Results Seven hundred twenty-four kidney transplants were included, 12% were living donors and 88% were deceased donors. The mean age was 54.8 in recipients and 53 in donors. Transplant renal artery stenosis was diagnosed in 70 (10%) recipients, the majority in the first 6 months after surgery. The 51% of patients with transplant renal artery stenosis were managed conservatively. The multivariate analysis showed diabetes mellitus, graft rejection, arterial resuture and donor body mass index as independent risk factors for transplant renal artery stenosis. Survival of the grafts with transplant renal artery stenosis was 98% at 6 months and 95% at two years. Conclusions The systematic performance of Doppler ultrasound in the immediate post-transplant period diagnosed 10% of transplant renal artery stenosis in our cohort. Despite the above risk factors, an adequate monitoring and treatment could avoid the increased risk of graft loss in patients with transplant renal artery stenosis. (AU)


Asunto(s)
Humanos , Masculino , Femenino , Obstrucción de la Arteria Renal , Trasplante de Riñón , Supervivencia de Injerto , Ultrasonografía Doppler , Estudios Retrospectivos
8.
Actas urol. esp ; 48(1): 79-104, Ene-Febr. 2024. graf, tab
Artículo en Inglés, Español | IBECS | ID: ibc-229109

RESUMEN

Introducción La litiasis en el receptor del injerto renal puede ser una enfermedad peligrosa cuyo riesgo potencial es el deterioro de la función renal. Adquisición de la evidencia Se realizó una búsqueda sistemática de la literatura hasta febrero del 2023. El objetivo primario era evaluar la incidencia de litiasis en receptores de trasplante renal (TR). El secundario era valorar el momento de formación, la localización y la composición de la litiasis, las opciones de tratamiento disponibles y la incidencia de la pérdida del injerto. Síntesis de la evidencia Un total de 41 estudios no aleatorizados compuestos por 699 pacientes cumplieron los criterios de inclusión. La edad en el momento del diagnóstico de la litiasis oscilaba entre 29 y 53 años. La incidencia de urolitiasis se encontraba entre 0,1 y 6,3%, siendo diagnosticada generalmente a los 12 meses del TR. La mayoría de las litiasis detectadas se localizaron en los cálices o en la pelvis. La composición más frecuente fue la de oxalato cálcico. Se consideraron diferentes estrategias de tratamiento como vigilancia activa, ureteroscopia, abordaje percutáneo/combinado o cirugía abierta. Del total de pacientes, 15,73% fueron tratados con litotricia extracorpórea por ondas de choque (LEOCh) y 26,75% se sometieron a litotricia endoscópica o extracción quirúrgica. De estos sujetos, 18,03% se abordaron mediante nefrolitotomía percutánea, mientras que 3,14% se sometieron a un manejo combinado. Se realizó litotomía quirúrgica en 5,01% de los casos. La tasa libre de litiasis (TLL) global se situó en torno a 80%. Conclusiones La litiasis en el TR es una patología poco frecuente que suele diagnosticarse al año de la cirugía. Su localización más común son los cálices y la pelvis renal, y en la mayoría de los casos está compuesta de oxalato cálcico. Todos los tratamientos activos han demostrado resultados satisfactorios en términos de TLL, ... . (AU)


Introduction Lithiasis in renal graft recipients might be a dangerous condition with a potential risk of organ function impairment. Evidence acquisition A systematic literature search was conducted through February 2023. The primary objective was to assess the incidence of lithiasis in kidney transplant (KT) recipients. The secondary objective was to assess the timing of stone formation, localization and composition of stones, possible treatment options, and the incidence of graft loss. Evidence synthesis A total of 41 non-randomized studies comprising 699 patients met our inclusion criteria. The age at lithiasis diagnosis ranged between 29-53 years. Incidence of urolithiasis ranged from 0.1 to 6.3%, usually diagnosed after 12 months from KT. Most of the stones were diagnosed in the calyces or in the pelvis. Calcium oxalate composition was the most frequent. Different treatment strategies were considered, namely active surveillance, ureteroscopy, percutaneous/combined approach, or open surgery. 15.73% of patients were submitted to extracorporeal shock wave lithotripsy (ESWL), while 26.75% underwent endoscopic lithotripsy or stone extraction. 18.03% of patients underwent percutaneous nephrolithotomy whilst 3.14% to a combined approach. Surgical lithotomy was performed in 5.01% of the cases. Global stone-free rate was around 80%. Conclusions Lithiasis in kidney transplant is a rare condition usually diagnosed after one year after surgery and mostly located in the calyces and renal pelvis, more frequently of calcium oxalate composition. Each of the active treatments is associated with good results in terms of stone-free rate, thus the surgical technique should be chosen according to the patient's characteristics and surgeon preferences. (AU)


Asunto(s)
Humanos , Trasplante de Riñón , Nefrolitiasis
9.
Nefrologia (Engl Ed) ; 2024 Feb 07.
Artículo en Español | MEDLINE | ID: mdl-38331599

RESUMEN

INTRODUCTION: It has been reported that after vaccination with RNAm or viral vectors from SARS-CoV-2 a significant number of solid organ transplant recipients do not develop an effective immune response. In this scenario, the use of tixagevimab-cilgavimab was approved by the European Medicines Agency for COVID-19 prophylaxis in immunocompromised patients in March 2022. We present our experience with a group of kidney transplant recipients who received prophylactic treatment with tixagevimab-cilgavimab. MATERIAL AND METHODS: Prospective study from a cohort of kidney transplant recipients who had been previously vaccinated with 4 doses and did not achieve a satisfactory immune response to vaccination, presenting antibody titers lower than 260 BAU/mL when measured by ELISA. A total of 55 patients who received a single dose of 150mg of tixagevimab and 150mg of cilgavimab between May and September of 2022 were included in this study. RESULTS: No immediate or severe adverse reactions, including worsening of kidney function, were observed after administering the drug or during follow up. All patients who had received the drug 3 months prior presented positive antibody titers (>260 BAU/mL). Seven patients were diagnosed with COVID, and one of those patients had to be admitted to the hospital and died 5 days later from infectious complications and a suspected diagnosis of bacterial coinfection. CONCLUSIONS: In our experience, all kidney transplant recipients reached antibody titers higher than 260 BAU/mL 3 months after receiving prophylactic treatment with tixagevimab-cilgavimab with no severe or irreversible adverse reactions.

10.
Actas Urol Esp (Engl Ed) ; 48(1): 79-104, 2024.
Artículo en Inglés, Español | MEDLINE | ID: mdl-37574010

RESUMEN

INTRODUCTION: Lithiasis in renal graft recipients might be a dangerous condition with a potential risk of organ function impairment. EVIDENCE ACQUISITION: A systematic literature search was conducted through February 2023. The primary objective was to assess the incidence of lithiasis in kidney transplant (KT) recipients. The secondary objective was to assess the timing of stone formation, localization and composition of stones, possible treatment options, and the incidence of graft loss. EVIDENCE SYNTHESIS: A total of 41 non-randomized studies comprising 699 patients met our inclusion criteria. The age at lithiasis diagnosis ranged between 29-53 years. Incidence of urolithiasis ranged from 0.1-6.3%, usually diagnosed after 12 months from KT. Most of the stones were diagnosed in the calyces or in the pelvis. Calcium oxalate composition was the most frequent. Different treatment strategies were considered, namely active surveillance, ureteroscopy, percutaneous/combined approach, or open surgery. 15.73% of patients were submitted to extracorporeal shock wave lithotripsy (ESWL), while 26.75% underwent endoscopic lithotripsy or stone extraction. 18.03% of patients underwent percutaneous nephrolithotomy whilst 3.14% to a combined approach. Surgical lithotomy was performed in 5.01% of the cases. Global stone-free rate was around 80%. CONCLUSIONS: Lithiasis in kidney transplant is a rare condition usually diagnosed after one year after surgery and mostly located in the calyces and renal pelvis, more frequently of calcium oxalate composition. Each of the active treatments is associated with good results in terms of stone-free rate, thus the surgical technique should be chosen according to the patient's characteristics and surgeon preferences.


Asunto(s)
Cálculos Renales , Trasplante de Riñón , Litiasis , Humanos , Adulto , Persona de Mediana Edad , Oxalato de Calcio , Cálculos Renales/epidemiología , Cálculos Renales/terapia , Riñón
11.
Actas Urol Esp (Engl Ed) ; 48(2): 177-183, 2024 Mar.
Artículo en Inglés, Español | MEDLINE | ID: mdl-37574014

RESUMEN

INTRODUCTION AND OBJECTIVES: Transplant renal artery stenosis (TRAS) is a vascular complication after kidney transplantation which estimated incidence is 13%. It could cause refractory arterial hypertension, kidney dysfunction and premature death in transplant recipients. METHODS: We carried out a retrospective study including every patient who underwent renal transplantation between 2014 and 2020. They were evaluated with a systematic post-transplant renal Doppler ultrasound. To identify independent risk factors for transplant renal artery stenosis we performed a multivariate analysis. RESULTS: Seven hundred twenty-four kidney transplants were included, 12% ​​were living donors and 88% were deceased donors. The mean age was 54.8 in recipients and 53 in donors. Transplant renal artery stenosis was diagnosed in 70 (10%) recipients, the majority in the first 6 months after surgery. 51% of patients with transplant renal artery stenosis were managed conservatively. The multivariate analysis showed diabetes mellitus, graft rejection, arterial resuture and donor body mass index as independent risk factors for transplant renal artery stenosis. Survival of the grafts with transplant renal artery stenosis was 98% at 6 months and 95% at two years. CONCLUSIONS: The systematic performance of Doppler ultrasound in the immediate post-transplant period diagnosed 10% of transplant renal artery stenosis in our cohort. Despite the above risk factors, an adequate monitoring and treatment could avoid the increased risk of graft loss in patients with transplant renal artery stenosis.


Asunto(s)
Obstrucción de la Arteria Renal , Humanos , Persona de Mediana Edad , Obstrucción de la Arteria Renal/diagnóstico por imagen , Obstrucción de la Arteria Renal/epidemiología , Obstrucción de la Arteria Renal/etiología , Incidencia , Estudios Retrospectivos , Resultado del Tratamiento , Factores de Riesgo , Ultrasonografía Doppler/efectos adversos
12.
Actas Urol Esp (Engl Ed) ; 48(2): 125-133, 2024 Mar.
Artículo en Inglés, Español | MEDLINE | ID: mdl-37604402

RESUMEN

INTRODUCTION: Kidney transplantation is the treatment of choice for patients with stage 5 chronic kidney disease (CKD). About 60% of CKD patients are overweight or obese at the time of kidney transplantation, and post-transplant obesity occurs in 50% of patients, with a weight gain of 10% in the first year and high risk of cardiovascular mortality. Obesity is associated with an increased risk of delayed graft function (DGF), acute rejection, surgical complications, graft loss and mortality. The aim of this study is to assess the clinical evolution of obese and overweight patients that have received a kidney transplant, based on short- and long-term complications associated with a higher BMI. MATERIAL AND METHODS: A descriptive, observational, cross-sectional study was conducted with 104 kidney or pancreas-kidney transplant patients between March 2017 and December 2020, with a follow-up until April 2021. For comparative analysis, patients were grouped according to BMI. RESULTS: Mean age was of 56.65 years, 60.6% male and 39.4 % female. Overweight patients experienced prolonged surgeries, more surgical wound dehiscence, delayed graft function, hernias, proteinuria and more indications for renal biopsies. Additionally, obese patients displayed more DGF, indications for renal biopsies, proteinuria, development of diabetes mellitus, atrial fibrillation and needed prolonged hospital stays. CONCLUSIONS: Despite a high prevalence of comorbidity in the overweight and/or obese population, we found no reduction in patient and/or graft survival. However, longer follow-up is needed.


Asunto(s)
Fallo Renal Crónico , Trasplante de Riñón , Humanos , Masculino , Femenino , Persona de Mediana Edad , Sobrepeso/complicaciones , Funcionamiento Retardado del Injerto/epidemiología , Funcionamiento Retardado del Injerto/complicaciones , Estudios Transversales , Rechazo de Injerto , Obesidad/complicaciones , Obesidad/epidemiología , Fallo Renal Crónico/complicaciones , Proteinuria/complicaciones
13.
Endocrinol Diabetes Nutr (Engl Ed) ; 70(10): 628-633, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-38065628

RESUMEN

INTRODUCTION: Weight gain and changes in body composition are associated with the onset of diabetes after kidney transplantation, and detailing these changes can help prevent this situation. The study aimed to assess the prevalence of diabetes mellitus after kidney transplantation and changes in the nutritional status and body composition in patients with diabetes one year from surgery. MATERIALS AND METHODS: This survey was a single-center, prospective cohort study. Twenty-nine patients over 18 years old who underwent isolated kidney transplantation, without diabetes, were included and followed up for one year. At hospital discharge after transplantation and one year later, anthropometric (weight, height and abdominal circumference), body composition (electrical bioimpedance), routine biochemical and dietary intake assessments were performed. RESULTS: Most of the patients were male (75%), and the mean age was 48.0±11.8 years old. In the first-year post-surgery 27.6% of patients had DM and the diagnosis was made, on average, 4 months after transplantation. The group with diabetes had, from the beginning to the end of the study, greater weight and body fat, especially abdominal fat. The non-diabetic group, after one year, showed an increase in phase angle, body weight and body masses, more pronounced of fat-free mass, when compared with fat mass gain. CONCLUSIONS: Both groups showed weight gain, but in the non-diabetic group these changes can be interpreted as an improvement in the nutritional profile. Metabolic abnormalities associated with immunosuppression and eating habits, combination that maintains increased the risk for diabetes for long time, keeping this group with priority in nutritional care.


Asunto(s)
Diabetes Mellitus , Estado Nutricional , Humanos , Masculino , Adulto , Persona de Mediana Edad , Adolescente , Femenino , Estudios Prospectivos , Diabetes Mellitus/epidemiología , Diabetes Mellitus/etiología , Composición Corporal , Aumento de Peso
14.
Actas urol. esp ; 47(10): 621-630, Dic. 2023. tab, graf
Artículo en Inglés, Español | IBECS | ID: ibc-228312

RESUMEN

Introducción: Los receptores de trasplante renal (TR) tienen al menos cuatro veces más riesgo de desarrollar neoplasias renales que la población general. Dado que estos pacientes suelen albergar tumores bilaterales o multifocales, el tratamiento de las masas renales sigue siendo un tema controvertido. Objetivo Explorar el tratamiento actual de las masas renales en riñones nativos de pacientes con TR. Adquisición de la evidencia Se realizó una búsqueda bibliográfica en la base de datos Medline/PubMed y se incluyeron 34 estudios en la presente revisión. Síntesis de la evidencia La vigilancia activa es una opción terapéutica factible en pacientes frágiles con masas renales menores de 3 cm. Dado que la cirugía conservadora de nefronas no está justificada en el caso de masas en el riñón nativo, la nefrectomía radical es el tratamiento estándar para los tumores renales en riñones nativos de receptores de TR, con técnicas laparoscópicas asociadas a tasas de complicaciones perioperatorias significativamente menores en comparación con el abordaje abierto. La realización de nefrectomía bilateral de riñón nativo y TR en el mismo acto puede ser una opción terapéutica en pacientes con masa renal y enfermedad poliquística renal, particularmente ante la ausencia de diuresis residual. Los pacientes con enfermedad localizada y nefrectomía radical satisfactoria no requieren ajuste del tratamiento inmunosupresor. En los casos con metástasis, los agentes mTOR pueden garantizar una respuesta antitumoral eficaz, manteniendo a la vez el tratamiento inmunosupresor adecuado para proteger el injerto. Conclusiones El cáncer renal en riñones nativos postrasplante es un acontecimiento frecuente. La nefrectomía radical es el tratamiento de elección en masas renales localizadas. Aún no se ha implementado una estrategia de cribado estandarizada y ampliamente aprobada para las neoplasias malignas en las unidades renales nativas. (AU)


Introduction: Kidney transplant (KT) recipients have a four-times higher risk of renal malignancies compared to general population. As these patients frequently harbor bilateral or multifocal tumors, the management of renal masses is still under debate. Objective To explore the current management of the native kidney masses in KT patients.Acquisition of evidenceWe performed a literature search on MEDLINE/PubMed database. A number of 34 studies were included in the present review. Synthesis of evidence In frail patients with renal masses below 3 cm, active surveillance is a feasible alternative. Nephron-sparing surgery is not justified for masses in the native kidney. Radical nephrectomy is the standard treatment for post-transplant renal tumors of the native kidneys in KT recipients, with laparoscopic techniques leading to significantly less perioperative complication rates as compared to the open approach. Concurrent bilateral native nephrectomy at the time of transplantation can be considered in patients with renal mass and polycystic kidney disease, especially if no residual urinary output is present. Patients with localized disease and successful radical nephrectomy do not require immunosuppression adjustment. In metastatic cases, mTOR agents can ensure efficient antitumoral response, while maintaining proper immunosuppression in order to protect the graft. Conclusions Post-transplant renal cancer of the native kidneys is a frequent occurrence. Radical nephrectomy is most frequently performed for localized renal masses. A standardized and widely-approved screening strategy for malignancies of native renal units is yet to be implemented. (AU)


Asunto(s)
Humanos , Trasplante de Riñón , Carcinoma de Células Renales , Nefrectomía , Terapia Neoadyuvante
15.
Enferm. nefrol ; 26(4): 337-343, oct. - dic. 2023. graf, tab
Artículo en Español | IBECS | ID: ibc-229057

RESUMEN

Introdución:El trasplante renal es la mejor terapia de reemplazo renal, el cual depende de múltiples factores para un funcionamiento como condiciones del donador, del receptor y sociodemográficas.Objetivo: Evaluar el efecto del sexo de los donadores y receptores durante el primer año después del trasplante en los valores de hemoglobina. Material y Método: Estudio de cohorte retrospectiva de receptores renales del 2014 al 2019, realizado en el Hospital de Especialidades del Centro Médico Nacional Siglo XXI (Ciudad de México). Se incluyeron a todos los trasplantados, excluyendo fallecidos, pérdida del injerto y pérdida de seguimiento en la institución. Se estudiaron sexo y edad del donante y receptor, tipo de donante renal (vivo o fallecido), hemoglobina antes del trasplante renal y la hemoglobina al año del trasplante, y creatinina sérica.Resultados: Se analizaron 914 pacientes, se excluyeron 109 por diversos motivos, quedando 805 pacientes que completaron los 12 meses de seguimiento. En el caso de donaciones de masculino a femenino, la mediana de hemoglobina del receptor a los 12 meses fue de 15,2 g/dL (Percentil 25-Percentil 75: 13,7-16,0 g/dL), de masculino a masculino de 15,2 g/dL (Percentil 25-Percentil 75: 13,4-16,6 g/dL), de femenino a femenino de 14,0 g/dL (Percentil 25-Percentil 75: 12,4-15,3 g/dL) y femenino de masculino de 13,5 g/dL (Percentil 25-Percentil 75: 12,5-14,8 g/dL).Conclusiones: Los niveles de hemoglogina no parecen estar influenciados por la masa nefronal, como sí otras funciones del injerto (depuración de creatinina). La regulación de la hemoglobina guarda relación con el sexo del receptor (AU)


Introduction: Kidney transplantation is the optimal renal replacement therapy, dependent on various factors such as donor, recipient, and sociodemographic conditions for optimal functioning. Objective: To assess the effect of donor and recipient sex during the first year post-transplant on hemoglobin values.Material and Method: A retrospective cohort study of kidney recipients from 2014 to 2019 was conducted at the Hospital de Especialidades of Centro Médico Nacional Siglo XXI (Mexico City). All transplant recipients were included, excluding those who died, experienced graft loss, or were lost to follow-up at the institution. Donor and recipient sex and age, type of renal donor (living or deceased), hemoglobin before renal transplant, hemoglobin at one-year post-transplant, and serum creatinine were studied.Results: A total of 914 patients were analyzed, with 109 excluded for various reasons, resulting in 805 patients who completed the 12-month follow-up. In cases of male-to-female donations, the median recipient hemoglobin at 12 months was 15.2 g/dL with an interquartile range (IQR 25-75) of 13.7-16.0 g/dL; male-to-male donations had a median of 15.2 g/dL (IQR 25-75 13.4-16.6 g/dL); female-to-female donations had a median of 14.0 g/dL (IQR 25-75 12.4-15.3 g/dL), and female-to-male donations had a median of 13.5 g/dL (IQR 25-75 12.5-14.8 g/dL).Conclusions: Hemoglobin levels do not appear to be influenced by nephron mass, as with other graft functions (creatinine clearance). Hemoglobin regulation is associated with the recipient’s sex (AU)


Asunto(s)
Trasplante de Riñón , Hemoglobinas , Sexo , Anemia , Trasplante de Órganos
16.
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1535981

RESUMEN

Contexto: la enfermedad renal crónica (ERC) tiene una alta morbimortalidad y un alto costo de tratamiento. Entre sus causas principales en Pediatría se describen las anomalías congénitas del riñón y las vías urinarias (CAKUT, por sus siglas en inglés) Objetivo: determinar la evolución y los factores asociados a mortalidad de una cohorte pediátrica atendida en dos hospitales de referencia nacional, con el fin de elaborar estrategias para el manejo precoz y multidisciplinario de esta enfermedad y, de esa manera, optimizar los recursos para reducir la morbimortalidad de la enfermedad. Metodología: estudio de cohorte retrospectivo de pacientes de dos hospitales de referencia entre enero del 2000 y diciembre del 2020, en el cual se estudiaron: edad, sexo, seguro social, ingreso fijo, causa de la ERC, estadio de la ERC al ingreso y al final de estudio, requerimiento y tipo de diálisis, trasplante y óbito, donde el estadio de la ERC se clasificó según las guías K/DOQI (Kidney Disease Quality Iniciative). Por su parte, se relacionó óbito con edad, sexo, ingreso fijo, seguro social, estadio de ERC y requerimiento de diálisis. Se destaca que el análisis se realizó con el programa Epi Info (Atlanta), el cual usa estadística descriptiva y la prueba de chi cuadrado para establecer asociaciones con óbito a un nivel de significancia de 0,05. Resultados: se estudió a 187 pacientes de entre 2 y 17 años de edad, 96 mujeres y 91 varones, donde la mayoría eran mayores de10 años (44,9 %). Entre las causas de ERC más frecuentes se encuentran las anomalías congénitas (CAKUT) (54,5 %) y las indeterminadas (16,6 %); el estadio de ERC al ingreso estuvo repartido entre I (2,1 %), II (16 %), III (25,7 %), IV (8 %), y V (48,1 %); además, el 59,4 % requirió diálisis, el 87,3 % hemodiálisis, el 12,6 % diálisis peritoneal y 13,3 % recibieron un trasplante; por último, la mortalidad fue del 24,5 %, lo cual se asoció con el estadio de ERC al ingreso y el requerimiento de diálisis. Conclusiones: este estudio de cohorte demostró mejores resultados en la evolución de los niños con ERC diagnosticados en estadios tempranos. El diagnóstico y tratamiento precoces ayudan a mejorar la morbimortalidad.


Background: Chronic kidney disease (CKD) has high morbidity and mortality and high cost of treatment. Among the main causes are congenital anomalies of the kidney and urinary tract (CAKUT). Purpose: To determine the evolution and factors associated with mortality in a pediatric cohort attended in two national referral hospitals, in order to develop strategies for early and multidisciplinary management of this disease and, thus, optimize resources to reduce morbidity and mortality of the disease. Methodology: Retrospective cohort study of patients in two reference hospitals between January 2000 and December 2020. Age, sex, social security, fixed income, cause of CKD, CKD stage at admission and at the end of study, requirement and type of dialysis, transplant and death were studied. CKD stage was classified according to the K/DOQI (Kidney Disease Quality Initiative) guidelines. Death was related to age, sex, fixed income, social security, CKD stage, and dialysis requirement. Data analysis was performed with the Epi Info program (CDC, Atlanta), using descriptive statistics, and the chi-square test to establish associations with death at a significance level of 0.05. Results: 187 patients between 2 and 17 years of age 96 women and 91 men, were studied. Most of the patients were older than 10 years (44.9%). Among the most frequent causes of CKD are congenital anomalies (CAKUT) (54.5%) and undetermined (16,6%). CKD stage at admission was I (2,1%), II (16%), III (25,7%), IV (8%), and V (48.1%). 59.4% required dialysis, hemodialysis (87.3%), peritoneal dialysis (12.7%), 13.3% underwent kidney transplant. Mortality rate was 24.5%, which was associated with CKD stage at admission and dialysis requirement. Conclusions: This cohort study demonstrated better outcomes in children with CKD diagnoses at its early stages. The early diagnosis and treatment help to improve the morbidity and mortality.

17.
Rev. Inst. Med. Trop ; 18(2)dic. 2023.
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1529466

RESUMEN

Introducción: El trasplante renal (TR) ha revolucionado la vida de los niños con Enfermedad Renal Crónica terminal (ERCT). Pero el requerimiento crónico de inmunosupresores aumenta el riesgo de complicaciones como son las infecciones. El objetivo del presente trabajo es describir las complicaciones infecciosas de pacientes pediátricos trasplantados renales en un centro de trasplante de referencia desde diciembre 2016 a mayo del 2023. Materiales y métodos: Estudio retrospectivo, observacional, descriptivo. Fueron incluidos pacientes menores de 18 años post operados de TR, en un centro de trasplante de referencia, que presentaron datos clínicos y laboratoriales compatibles con procesos infecciosos, desde diciembre del 2016 a mayo del 2023. Resultados: Fueron incluidos 18 pacientes post trasplantes, de donante vivo (56%), donante cadavérico (44%). Edad promedio: 12,3 años. Masculino (56%), femenino (44%). En 16 (88%) pacientes se presentó alguna complicación. Quince pacientes (83%) fueron complicaciones de naturaleza infecciosa. Entre las infecciones encontradas se tuvieron: infecciones urinarias: 4/18 (22%) (gérmenes aislados: E. Coli, Klebsiella Pneumoniae y Candida), infecciones cutáneas: 2/18 (11%), infecciones virales: Citomegalovirus: 1/18, BK virus: 3/18, Varicela Zoster: 1/18. Arbovirus: Dengue: 3/18 (16%). Chikungunya 2/18 (11%). COVID-19: 4/18 (22%). Enfermedad diarreica: 2/18 (Giardia lamblia y Clostridium difficile). Conclusión: Las infecciones en trasplantados en la presente serie fueron frecuentes. No se presentaron pérdida del injerto renal, ni óbitos.

18.
Vive (El Alto) ; 6(18): 961-971, dic. 2023.
Artículo en Español | LILACS | ID: biblio-1530589

RESUMEN

La enfermedad renal crónica (ERC) es un problema sanitario mundial que afecta al 10% de la población. Su prevalencia ha ido en aumento debido a factores relacionados con el estilo de vida y el envejecimiento de la población. Objetivo. Analizar la percepción de los pacientes receptores de trasplantes renales sobre su calidad de vida, y evaluar los factores que influyen en la calidad de vida post-trasplante renal. Metodología. Para ello, se llevó cabo un estudio bibliográfico considerando fuentes de bases de datos académicas como PubMed, Scopus, Web of Science, entre otras. Donde se usaron como descriptores de búsqueda "trasplante renal", "calidad de vida", "percepción del paciente", "resultados post-trasplante". Además, la búsqueda se amplió en revistas especializadas, tesis, libros y conferencias relacionadas con el tema. como criterios de inclusión fueron considerados estudios originales, revisiones sistemáticas, metaanálisis, publicaciones en los últimos 10 años, etc. Y como exclusión fueron considerados estudios no relacionados, artículos de opinión, publicaciones en idiomas no accesibles. En cuanto al proceso extracción de la información, se usó la matriz de registro y las técnicas de observación y análisis documental, la matriz quedo constituida por Autor(es), año de publicación, país de origen, objetivos del estudio, metodología utilizada, variables analizadas, resultados principales, y conclusiones relevantes. Conclusión. Es esencial reconocer que la calidad de vida post-trasplante renal es una experiencia subjetiva que varía significativamente entre los pacientes y que está influenciada por una amplia gama de factores, que van desde la gestión de síntomas físicos hasta el manejo de desafíos psicológicos y sociales.


Chronic kidney disease (CKD) is a worldwide health problem affecting 10% of the population. Its prevalence has been increasing due to factors related to lifestyle and population aging. Objective. To analyze the perception of renal transplant recipients on their quality of life, and to evaluate the factors that influence post renal transplant quality of life. Methodology. For this purpose, a bibliographic study was carried out considering sources of academic databases such as PubMed, Scopus, Web of Science, among others. The search descriptors used were "renal transplant", "quality of life", "patient perception", "post-transplant results". In addition, the search was extended to specialized journals, theses, books and conferences related to the subject. Inclusion criteria included original studies, systematic reviews, meta-analysis, publications in the last 10 years, etc. Unrelated studies, opinion articles, publications in non-accessible languages were considered as exclusion criteria. As for the information extraction process, the registration matrix and the techniques of observation and documentary analysis were used, the matrix was made up of author(s), year of publication, country of origin, objectives of the study, methodology used, variables analyzed, main results, and relevant conclusions. Conclusion. It is essential to recognize that post-renal transplant quality of life is a subjective experience that varies significantly among patients and is influenced by a wide range of factors, ranging from the management of physical symptoms to the management of psychological and social challenges.


A doença renal crônica (DRC) é um problema de saúde global que afeta 10% da população. Sua prevalência tem aumentado devido a fatores de estilo de vida e ao envelhecimento da população. Objetivo. Analisar a percepção dos receptores de transplante renal sobre sua qualidade de vida e avaliar os fatores que influenciam a qualidade de vida pós-transplante renal. Metodologia. Para isso, foi realizado um estudo bibliográfico considerando fontes de bancos de dados acadêmicos como PubMed, Scopus, Web of Science, entre outros. Os descritores de busca utilizados foram "transplante renal", "qualidade de vida", "percepção do paciente", "resultados pós-transplante" Além disso, a busca foi estendida a periódicos especializados, teses, livros e congressos relacionados ao tema. Os critérios de inclusão incluíram estudos originais, revisões sistemáticas, meta-análises, publicações nos últimos 10 anos, etc. Estudos não relacionados, artigos de opinião e publicações em idiomas não acessíveis foram considerados como critérios de exclusão. Quanto ao processo de extração de informações, foram utilizadas a matriz de registro e as técnicas de observação e análise documental. A matriz foi composta por autor(es), ano de publicação, país de origem, objetivos do estudo, metodologia utilizada, variáveis analisadas, principais resultados e conclusões relevantes. Conclusões. É essencial reconhecer que a qualidade de vida pós-transplante renal é uma experiência subjetiva que varia significativamente entre os pacientes e é influenciada por uma ampla gama de fatores, que vão desde o controle dos sintomas físicos até o enfrentamento de desafios psicológicos e sociais.


Asunto(s)
Bibliografías como Asunto , PubMed
19.
Nefrologia (Engl Ed) ; 43(5): 606-615, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37981563

RESUMEN

INTRODUCTION AND OBJECTIVES: There is currently no doubt that a kidney transplant with good function is the best treatment we can offer a child with severe kidney failure, improving their growth, development and life in general. But there are few works that follow these patients over the years to find out what their life is like as adults, their achievements and if there are any difficulties that may have arisen from their illness. That has been the objective of this work. MATERIAL AND METHODS: We have collected the evolution of 287 patients who received at least one kidney transplant in pediatric age, analyzing not only the survival of grafts and recipients but, fundamentally, their current quality of life. RESULTS: Over a 40-year period (1979-2019), 345 kidney transplants were performed in 287 pediatric recipients, with a rate of retransplantation before reaching the age of majority of 16.7%. Survival, both of patients and grafts, has improved remarkably in the last 20 years. The survival of transplanted patients in the period from 1979 to 1996 at 10, 20 and 25 years after the intervention was 83%, 76% and 65% respectively, and 94% and 82% at 10 and 20 years respectively in those transplanted in the period from 1997 to 2019. Graft survival in the period from 1979 to 1996 at 10 and 20 years was 39% and 18%, increasing in the second period to 68% and 34% respectively. Survival of the first living donor graft (LD) at 5 and 10 years was 94% and 89%. Currently 150 of these patients are adults. Of these, 32% have a stable partner and 6.6% have children. The level of training is lower than that of the general population and many of them have other comorbidities. CONCLUSIONS: The life expectancy of pediatric patients with kidney failure transplanted during childhood has improved markedly in recent decades, as has graft survival, being better with a living donor. In general, they consider themselves satisfied with their lives, with great acceptance of their illness and limitations, but -analyzing their testimonies- we conclude that they lack social support, both for themselves and their families, to achieve a higher level of education and better quality of life.


Asunto(s)
Trasplante de Riñón , Insuficiencia Renal , Adulto , Niño , Humanos , Calidad de Vida , Donadores Vivos , Supervivencia de Injerto
20.
Nefrologia (Engl Ed) ; 43(5): 622-635, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-38000944

RESUMEN

The most widely used approach in the immunotherapy treatment of cancer is the administration of monoclonal antibodies directed against regulatory molecules of immune control that inhibit the activation of T cells, the so-called check point inhibitors (ICI). ICI nephrotoxicity epidemiology and pathology; its diagnosis with or without kidney biopsy; the type and duration of treatment; the possibility of rechallenging after kidney damage; and its indication in patients with cancer and renal transplantation are certainly controversial. In the absence of definitive studies, this document is intended to specify some recommendations agreed by the group of Onconephrology experts of the Spanish Society of Nephrology in those areas related to ICI nephrotoxicity, in order to help decision-making in daily clinical practice in Onconephrology consultations.


Asunto(s)
Enfermedades Renales , Neoplasias , Nefrología , Humanos , Neoplasias/complicaciones , Neoplasias/tratamiento farmacológico , Riñón , Anticuerpos Monoclonales
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...